0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Gemcitabine"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Pancreatic Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Pancreatic Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
EUR$2,789USDGBP
Bladder Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Bladder Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
EUR$2,789USDGBP
Advanced Pancreatic Cancer Drug Pipeline Analysis 2025 - Product Thumbnail Image

Advanced Pancreatic Cancer Drug Pipeline Analysis 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
EUR$2,789USDGBP
Urothelial Carcinoma Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Urothelial Carcinoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
EUR$2,789USDGBP
Bladder Cancer Pipeline Analysis Report - Product Thumbnail Image

Bladder Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
EUR$2,789USDGBP
Pancreatic Cancer Pipeline Analysis Report - Product Thumbnail Image

Pancreatic Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
EUR$2,789USDGBP
From
EUR$4,850USDGBP
From
EUR$7,950USDGBP
From
EUR$7,500USDGBP
Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
EUR$2,750USDGBP
From
EUR$9,500USDGBP
From
EUR$4,750USDGBP
Gemcitabine Hydrochloride Market 2024-2028 - Product Thumbnail Image

Gemcitabine Hydrochloride Market 2024-2028

  • Report
  • July 2024
  • 132 Pages
  • Global
From
EUR$2,500USDGBP
Loading Indicator

Gemcitabine is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a nucleoside analog, meaning it works by interfering with the growth of cancer cells. Gemcitabine is typically used in combination with other drugs, such as cisplatin, to treat non-small cell lung cancer (NSCLC). It is also used to treat small cell lung cancer (SCLC). Gemcitabine is generally well-tolerated, with few side effects. Gemcitabine is a widely used drug in the treatment of lung cancer. It is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and SCLC. It is also approved for use in combination with other drugs for the treatment of advanced NSCLC. The market for Gemcitabine is highly competitive, with many companies offering the drug. Some of the major players in the market include Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, and Roche. Other companies offering the drug include AstraZeneca, Novartis, and Teva Pharmaceuticals. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more